Share on StockTwits

Equities researchers at Cowen and Company lifted their price objective on shares of Amgen (NASDAQ:AMGN) from $131.00 to $145.00 in a research report issued on Thursday. Cowen and Company’s price objective would indicate a potential upside of 15.49% from the company’s current price.

A number of other analysts have also recently weighed in on AMGN. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Amgen in a research note on Wednesday. They now have a $160.00 price target on the stock, up previously from $149.00. Separately, analysts at Nomura reiterated a “neutral” rating on shares of Amgen in a research note on Wednesday. They now have a $142.00 price target on the stock, up previously from $129.00. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Amgen in a research note on Wednesday. They now have a $159.00 price target on the stock, up previously from $155.00. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $139.17.

Amgen (NASDAQ:AMGN) traded down 1.44% on Thursday, hitting $125.55. 4,543,694 shares of the company’s stock traded hands. Amgen has a 52-week low of $103.31 and a 52-week high of $131.24. The stock has a 50-day moving average of $120.1 and a 200-day moving average of $119.0. The company has a market cap of $95.292 billion and a price-to-earnings ratio of 19.51.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.37 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.07 by $0.30. The company had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter last year, the company posted $1.89 earnings per share. Amgen’s revenue was up 10.7% compared to the same quarter last year. Analysts expect that Amgen will post $8.36 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Thursday, August 14th will be paid a dividend of $0.61 per share. This represents a $2.44 annualized dividend and a dividend yield of 1.94%. The ex-dividend date is Tuesday, August 12th.

Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.